ECM2 and breast carcinoma: To further confirm the therapeutic efficacy of HOXB2/MATN3 or HOXB2/ECM2 transcriptional axis, we performed IHC for HOXB2, MATN3, and ECM2 in-house with 100 human tissue samples of patients with breast cancer (Fig. 7a).